艾司西酞普兰联合rTMS治疗癫痫共患抑郁的对照研究

注册号:

Registration number:

ChiCTR2100043834 

最近更新日期:

Date of Last Refreshed on:

2021-07-01 01:14:18 

注册时间:

Date of Registration:

2021-03-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

艾司西酞普兰联合rTMS治疗癫痫共患抑郁的对照研究

Public title:

A controlled study of escitalopram combined with rTMS in the treatment of epileptic depression

注册题目简写:

English Acronym:

研究课题的正式科学名称:

艾司西酞普兰联合rTMS治疗癫痫共患抑郁的对照研究

Scientific title:

A controlled study of escitalopram combined with rTMS in the treatment of epileptic depression

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

韩永凯 

研究负责人:

韩永凯 

Applicant:

Han YongKai 

Study leader:

Han YongKai 

申请注册联系人电话:

Applicant telephone:

+86 15836044966

研究负责人电话:

Study leader's
telephone:

+86 15836044966

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

37778870@qq.com

研究负责人电子邮件:

Study leader's E-mail:

37778870@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河南省新乡市前进路河南省精神卫生中心

研究负责人通讯地址:

河南省新乡市前进路河南省精神卫生中心

Applicant address:

Henan Mental Health Center, Qianjin Road, Xinxiang, Henan, China

Study leader's address:

Henan Mental Health Center, Qianjin Road, Xinxiang, Henan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

新乡医学院第二附属医院

Applicant's institution:

The Second Affiliated Hospital of Xinxiang Medical College

研究负责人所在单位:

新乡医学院第二附属医院

Affiliation of the Leader:

The Second Affiliated Hospital of Xinxiang Medical College

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

XYEFYLL-2021-11

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

新乡医学院第二附属医院伦理委员会

Name of the ethic committee:

The Ethics Committee of the Second Affiliated Hospital of Xinxiang Medical College

伦理委员会批准日期:

Date of approved by ethic committee:

2021-03-02 00:00:00

伦理委员会联系人:

赵明军

Contact Name of the ethic committee:

Zhao MingJun

伦理委员会联系地址:

河南省新乡市前进路河南省精神卫生中心

Contact Address of the ethic committee:

Henan Mental Health Center, Qianjin Road, Xinxiang, Henan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

河南省精神心理疾病临床医学研究中心

Primary sponsor:

Henan Mental Health Center

研究实施负责(组长)单位地址:

河南省前进路河南省精神卫生中心

Primary sponsor's address:

Henan Mental Health Center, Qianjin Road, Xinxiang, Henan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河南

市(区县):

新乡

Country:

China

Province:

Henan

City:

Xinxiang

单位(医院):

新乡医学院第二附属医院

具体地址:

前进路

Institution
hospital:

The Second Affiliated Hospital of Xinxiang Medical College

Address:

Qianjin Road

经费或物资来源:

河南省精神心理疾病临床医学研究中心

Source(s) of funding:

Henan Mental Health Center, Qianjin Road, Xinxiang City, Henan Province, China

研究疾病:

癫痫共患抑郁  

Target disease:

Epilepsy suffers from depression

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究采用病例对照的研究方法,将癫痫共患抑郁患者分为研究组与对照组。对照组采用艾司西酞普兰治疗,研究组采用艾司西酞普兰联合低频重复经颅磁刺激治疗,2组均于治疗4周后评定临床疗效,采用匹斯堡睡眠质量指数量表(PSQI)、汉密尔顿抑郁量表24项版(HAMD-24)、癫痫患者生活质量量表31项中文版评价患者睡眠质量、抑郁程度及生活质量变化,观察不良反应,并检测治疗前后炎性因子如IL-1β、IL-6水平变化情况以客观反映治疗效果,进而为临床治疗癫痫共患抑郁方案的制定提供可靠数据支持。  

Objectives of Study:

In this study, patients with epilepsy comorbidities with depression were divided into study group and control group by case-control method.Control group treated with escitalopram citalopram, the team used escitalopram citalopram in combination with low-frequency repetitive transcranial magnetic stimulation treatment, two groups are in 4 weeks after treatment to assess the clinical curative effect, the Pittsburgh sleep quality index scale (PSQI) and Hamilton depression scale 24 edition (HAMD - 24), the Chinese version of 31 epilepsy patients quality of life scale for evaluating patients sleep quality, degree of depression and quality of life change, observe adverse reactions, and beta test before and after the treatment of inflammatory factors such as IL - 1, IL - 6 level changes in order to objectively reflect the treatment effect,Furthermore, it provides reliable data support for the formulation of clinical treatment of epileptic comorbiosis depression.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1)合并中枢神经系统疾病如脑梗死、脑出血;
2)并发其他精神疾病;
3)合并严重心肝肾疾病;
4)妊娠期和哺乳期妇女;
5)存在严重自杀倾向;
6)已知有酒精或药物成瘾史或滥用史;
7)入组前存在异常实验室指标者(如转氨酶超出正常上限3倍以上,血清钠低于正常水平,白细胞计数<2.8×10^9/L等);
8)入组前应用其他试验药物的;
9)不能依从治疗的。

Exclusion criteria:

1) Complicated central nervous system diseases such as cerebral infarction and cerebral hemorrhage;
2) Complicated with other mental disorders;
3) Complicated with serious heart, liver and kidney diseases;
4) Pregnant and lactating women;
5) Severe suicidal tendencies;
6) A known history of alcohol or drug addiction or abuse;
7) Abnormal laboratory indicators existed before enrollment (such as transaminase exceeding 3 times the upper limit of normal, serum sodium lower than normal, white blood cell count < 2.8 x 10^9 / L, etc.);
8) Other experimental drugs were used before enrollment;
9) Unable to comply with treatment.

研究实施时间:

Study execute time:

From 2021-03-03 00:00:00 To 2024-03-02 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-06-01 00:00:00 To 2024-03-02 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

47

Group:

experimental group

Sample size:

干预措施:

艾司西酞普兰联合低频重复经颅磁刺激

干预措施代码:

Intervention:

Escitalopram citalopram combined with repetitive transcri magnetic stimulus

Intervention code:

组别:

对照组

样本量:

47

Group:

control group

Sample size:

干预措施:

艾司西酞普兰

干预措施代码:

Intervention:

Escitalopram citalopram

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河南 

市(区县):

 

Country:

China

Province:

Henan

City:

单位(医院):

新乡医学院第二附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Affiliated Hospital of Xinxiang Medical College

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

汉密尔顿抑郁量表

指标类型:

主要指标

Outcome:

Hamilton Depression Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机方法使用最小化动态随机的方法。

Randomization Procedure (please state who generates the random number sequence and by what method):

In the random method, the method of minimizing dynamic randomness was used.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国临床试验注册中心

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Chinese Clinical Trial Registry

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-03-04 09:18:37